Parkinson's disease without expected neuropathologic abnormality

Journal of the American Medical Directors Association

Volumn 5, Issue 6, 2004, Pages 407-409

  Velickovic, Miodrag ^a   Lesser, Gerson ^a   Purohit, Dushyant ^a   Neufeld, Richard R ^a   Tarshish, Chaim Y ^a,b   Libow, Leslie S ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Alzheimer's disease; L dopa toxicity; Lewy bodies; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CARBIDOPA PLUS LEVODOPA;

AGED; ARTICLE; AUTOPSY; BRAIN NERVE CELL; CASE REPORT; CELL COUNT; CELL LOSS; CLINICAL FEATURE; DISEASE COURSE; DRUG RESPONSE; DRUG USE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOCHEMISTRY; LEWY BODY; MALE; MEDICAL SPECIALIST; NEUROLOGY; NEUROPATHOLOGY; NEUROTOXICITY; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

EID: 9444221481     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70010-9     Document Type: Article

References (15)

1. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - A prospective study. Can J Neurol Sci 1991;18:275-278.
2. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
3. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
4. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000; 247(suppl 2):II/3-II/10.
5. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-535.
6. Rajput AH, Fenton M, Birdi S, et al. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
7. Quinn N, Parkes D, Janota I, et al. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
8. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
9. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-2414.
10. Busch C, Bohl J, Ohm TO. Spatial, temporal and numeric analysis of Alzheimer changes in the nucleus coeruleus. Neurobiol Aging 1997;18: 401-406.
11. Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinson's disease: Clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord 2003;9:225-231.
12. Hyman BT, Trojanowski JQ. Editorial on Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-1097.
13. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: A population-based prospective study. J Am Geriatr Soc 2000;48:938-942.
14. Gross JS, Neufeld RR, Libow LS, et al. Autopsy study of the elderly institutionalized patient. Review of 234 autopsies. Arch Intern Med 1988;148:173-176.
15. Perl DP, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: Distinct entities on extremes of a spectrum of neurodegeneration? Ann Neurol 1998;44(suppl 1):S19-31.